Ovarian and Prostate Cancer (PARPi) [Tissue, Somatic]
BRCA1, BRCA2 and HRR testing for Ovarian and Prostate cancer in the context of PARP inhibitor prescription (FFPE). This EQA is sponsored.
NGS for somatic SNVs and indels – tumour with germline subtraction analysis
EQA for quality of NGS for somatic SNVs and indels <50bp (FFPE). For NGS requiring a matched normal control germline sample (single gene, panel testing, whole exome sequencing or whole genome sequencing). Pilot EQA.
NGS for somatic SNVs and indels – tumour testing only
EQA for quality of NGS for somatic SNVs and indels <50bp (FFPE). For NGS NOT requiring a matched normal control germline sample (single gene, panel testing, whole exome sequencing or whole genome sequencing). Pilot EQA.
Breast Cancer (AKT Pathway Gene Testing) [Tissue]
PIK3CA, AKT1 and PTEN gene testing in breast cancer (FFPE)
Breast Cancer (ESR1 and PIK3CA cfDNA Testing) [Plasma]
ESR1 and PIK3CA testing in cfDNA (plasma) for metastatic breast cancer. This EQA is sponsored.
Comprehensive Genomic Profiling (CGP)
Identification of different types of variants and genomic signatures by CGP in solid tumour (FFPE). This is a pilot EQA (genotyping only), places are limited, complete the form to express interest in participation (see participant information section).